EA019998B9 - Терапия глатирамером ацетатом с низкой кратностью - Google Patents
Терапия глатирамером ацетатом с низкой кратностьюInfo
- Publication number
- EA019998B9 EA019998B9 EA201270292A EA201270292A EA019998B9 EA 019998 B9 EA019998 B9 EA 019998B9 EA 201270292 A EA201270292 A EA 201270292A EA 201270292 A EA201270292 A EA 201270292A EA 019998 B9 EA019998 B9 EA 019998B9
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- glatiramer acetate
- multiple sclerosis
- low frequency
- patient
- relapsing
- Prior art date
Links
- 108010072051 Glatiramer Acetate Proteins 0.000 title abstract 2
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 title abstract 2
- 229960003776 glatiramer acetate Drugs 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 abstract 2
- 238000010254 subcutaneous injection Methods 0.000 abstract 2
- 239000007929 subcutaneous injection Substances 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27468709P | 2009-08-20 | 2009-08-20 | |
| US33761210P | 2010-02-11 | 2010-02-11 | |
| PCT/US2010/002283 WO2011022063A1 (en) | 2009-08-20 | 2010-08-19 | Low frequency glatiramer acetate therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EA201270292A1 EA201270292A1 (ru) | 2012-12-28 |
| EA019998B1 EA019998B1 (ru) | 2014-07-30 |
| EA019998B9 true EA019998B9 (ru) | 2016-01-29 |
Family
ID=43605835
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201270292A EA019998B9 (ru) | 2009-08-20 | 2010-08-19 | Терапия глатирамером ацетатом с низкой кратностью |
| EA201400394A EA032283B1 (ru) | 2009-08-20 | 2010-08-19 | Терапия глатирамером ацетатом с низкой кратностью |
| EA201691347A EA032287B1 (ru) | 2009-08-20 | 2010-08-19 | Терапия глатирамером ацетатом с низкой кратностью |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201400394A EA032283B1 (ru) | 2009-08-20 | 2010-08-19 | Терапия глатирамером ацетатом с низкой кратностью |
| EA201691347A EA032287B1 (ru) | 2009-08-20 | 2010-08-19 | Терапия глатирамером ацетатом с низкой кратностью |
Country Status (34)
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2527760T3 (es) * | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| US8077333B2 (en) * | 2002-09-09 | 2011-12-13 | Canon Kabushiki Kaisha | Printing control apparatus and printing control method |
| SG10201405806SA (en) * | 2009-08-20 | 2014-11-27 | Yeda Res & Dev | Low Frequency Glatiramer Acetate Therapy |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| US8759302B2 (en) | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| ES2602977T3 (es) | 2010-10-11 | 2017-02-23 | Teva Pharmaceutical Industries Ltd. | Biomarcadores de citocinas como biomarcadores predictivos de la respuesta clínica para acetato de glatirámero |
| AU2012323345A1 (en) | 2011-10-10 | 2014-05-22 | Teva Pharmaceutical Industries Ltd. | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
| MX2015004563A (es) | 2012-10-10 | 2015-07-14 | Teva Pharma | Biomarcadores predictivos para respuesta clinica para acetato de glatiramero. |
| EP2941274A4 (en) * | 2013-01-04 | 2016-11-16 | Teva Pharma | CHARACTERIZATION OF A MEDICINAL PRODUCT ASSOCIATED WITH GLATIRAMÈRE ACETATE |
| UY35790A (es) * | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| CN103641897B (zh) * | 2013-11-27 | 2017-01-04 | 深圳翰宇药业股份有限公司 | 一种合成醋酸格拉替雷的方法 |
| US9763992B2 (en) | 2014-02-13 | 2017-09-19 | Father Flanagan's Boys' Home | Treatment of noise induced hearing loss |
| WO2015195605A1 (en) * | 2014-06-17 | 2015-12-23 | Teva Pharmaceutical Industries Ltd. | Transmucosal delivery of glatiramer acetate by oral patches |
| CN104844697B (zh) * | 2014-09-26 | 2018-10-23 | 深圳翰宇药业股份有限公司 | 醋酸格拉替雷的制备方法 |
| US9155775B1 (en) * | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
| CN107550853B (zh) * | 2016-06-30 | 2020-06-12 | 深圳翰宇药业股份有限公司 | 一种醋酸格拉替雷注射液的制备方法 |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| CN109982712A (zh) | 2016-08-31 | 2019-07-05 | Mapi医药公司 | 包含醋酸格拉替雷的储库系统 |
| EP3551034A1 (en) | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| BR112019017724A2 (pt) | 2017-03-26 | 2020-03-31 | Mapi Pharma Ltd. | Sistemas depot de glatiramer para tratar formas progressivas de esclerose múltipla |
| WO2019002228A1 (en) | 2017-06-26 | 2019-01-03 | Institut Pasteur | TREATMENTS TO REMOVE HIV RESERVOIRS AND REDUCE VIRAL LOAD |
| US20200306516A1 (en) | 2017-08-14 | 2020-10-01 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with glatiramer or a pharmaceutically acceptable salt thereof |
| EP4003338A1 (en) | 2019-07-22 | 2022-06-01 | Actelion Pharmaceuticals Ltd | Methods of treating multiple sclerosis |
| KR102519053B1 (ko) | 2021-02-08 | 2023-04-06 | 건국대학교 산학협력단 | 염산가스의 농도 측정을 위한 수분 전처리 시스템 |
| KR102519054B1 (ko) | 2021-03-12 | 2023-04-06 | 건국대학교 산학협력단 | 나피온 드라이어와 수분 전처리장치의 결합시스템 |
| CA3220684A1 (en) | 2021-10-11 | 2023-04-20 | Actelion Pharmaceuticals Ltd | Methods of treating multiple sclerosis |
| US11951097B2 (en) * | 2021-10-11 | 2024-04-09 | Vanda Pharmaceuticals Inc. | Methods of treating multiple sclerosis |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050014694A1 (en) * | 2000-06-05 | 2005-01-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| US20070037740A1 (en) * | 2003-03-04 | 2007-02-15 | Irit Pinchasi | Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis |
| US20090048181A1 (en) * | 2004-09-02 | 2009-02-19 | Schipper Hyman M | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis |
| US20090149541A1 (en) * | 2007-11-28 | 2009-06-11 | Yafit Stark | Method of delaying the onset of clinically definite multiple sclerosis |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL36670A (en) | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
| DE3673317D1 (de) | 1985-10-11 | 1990-09-13 | Duphar Int Res | Automatische spritze. |
| US5981485A (en) | 1997-07-14 | 1999-11-09 | Genentech, Inc. | Human growth hormone aqueous formulation |
| IL113812A (en) | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
| US6214791B1 (en) | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
| IL119989A0 (en) | 1997-01-10 | 1997-04-15 | Yeda Res & Dev | Pharmaceutical compositions for oral treatment of multiple sclerosis |
| US6454746B1 (en) | 1997-06-04 | 2002-09-24 | Eli Lilly And Company | Medication delivery apparatus |
| JP2003521448A (ja) | 1998-07-23 | 2003-07-15 | ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ | 合成ペプチドおよび自己免疫疾患治療のための使用方法 |
| ES2527760T3 (es) | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| WO2000005250A1 (en) | 1998-07-23 | 2000-02-03 | Yeda Research And Development Co., Ltd | Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides |
| US6514938B1 (en) | 1998-09-25 | 2003-02-04 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| EP2090583B1 (en) | 1998-09-25 | 2011-07-13 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| AU6281599A (en) | 1998-10-02 | 2000-04-26 | Yeda Research And Development Co. Ltd. | Alternate day administration of copolymer 1 for treating autoimmune diseases |
| AU775073C (en) | 1998-11-12 | 2007-05-03 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD |
| PL202369B1 (pl) | 1999-08-27 | 2009-06-30 | Genentech Inc | Zastosowanie przeciwciała skierowanego przeciw ErbB2, zastosowanie przeciwciała skierowanego przeciw ErbB oraz zestaw zawierający to przeciwciało |
| EP1248643B1 (en) | 2000-01-20 | 2005-08-17 | YEDA RESEARCH AND DEVELOPMENT Co. LTD. | The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy |
| ZA200206457B (en) | 2000-02-18 | 2003-08-13 | Yeda Res & Dev | Oral, nasal and pulmonary dosage formulations of copolymer 1. |
| JP2003522799A (ja) | 2000-02-18 | 2003-07-29 | イエダ・リサーチ・アンド・ディベロップメント・カンパニー・リミテッド・アット・ザ・ウェイズマン・インスティテュート・オブ・サイエンス | コポリマー１の経口、経鼻および経肺投与製剤 |
| PL363431A1 (en) | 2000-06-05 | 2004-11-15 | Teva Pharmaceuticals Industries, Ltd. | The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| DE60116467T2 (de) | 2000-06-07 | 2006-11-02 | Yeda Research And Development Co., Ltd. | Verwendung des Copolymer-1 Peptids sowie von damit verwandten Peptiden und Polypeptiden und von damit behandelten T-Zellen zur Neuroprotektion gegen die Toxizität von Glutamat |
| WO2002076503A1 (en) | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| CA2469393C (en) | 2001-12-04 | 2010-05-25 | Teva Pharmaceutical Industries, Ltd. | Processes for the measurement of the potency of glatiramer acetate |
| EP1565486A2 (en) | 2002-11-13 | 2005-08-24 | Apotex Pharmachem Inc. | Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine |
| CN100464796C (zh) | 2002-11-25 | 2009-03-04 | 特克法马许可公司 | 包括可复位安全释放设备的自动注射器 |
| US7274347B2 (en) | 2003-06-27 | 2007-09-25 | Texas Instruments Incorporated | Prevention of charge accumulation in micromirror devices through bias inversion |
| NZ569331A (en) | 2003-01-21 | 2010-08-27 | Yeda Res & Dev | COP 1 for treatment of inflammatory bowel diseases |
| HRP20140524T1 (hr) * | 2003-05-14 | 2014-12-19 | Teva Pharmaceutical Industries Ltd. | Kombinacijska terapija glatiramer acetatom i mitoksantronom za lijeäśenje multiple skleroze |
| US20050170004A1 (en) | 2003-10-31 | 2005-08-04 | Vered Rosenberger | Nanoparticles for drug delivery |
| HUP0303779A2 (en) * | 2003-11-20 | 2006-02-28 | Richter Gedeon Vegyeszet | Pharmaceutical compositions containing hyaluronan complex for the treatment of sclerosis multiplex |
| CA2558380A1 (en) | 2004-03-03 | 2005-09-15 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and riluzole |
| MXPA06011021A (es) * | 2004-03-25 | 2007-04-13 | Johnson & Johnson | Compuestos de imidazol. |
| RU2410115C2 (ru) | 2004-05-07 | 2011-01-27 | Пептиммьюн, Инк. | Способы лечения заболеваний с помощью статистических сополимеров |
| US7655221B2 (en) | 2004-05-07 | 2010-02-02 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
| US20060194725A1 (en) | 2004-05-07 | 2006-08-31 | James Rasmussen | Methods of treating disease with random copolymers |
| US20060229233A1 (en) * | 2004-06-25 | 2006-10-12 | Id Biomedical Corporation | Compositions and methods for treating neurological disorders |
| NZ554018A (en) | 2004-09-09 | 2009-06-26 | Teva Pharma | Process for preparation of trifluoroacetyl glatiramer acetate using purified hydrobromic acid |
| DK1797109T3 (en) | 2004-09-09 | 2016-04-11 | Yeda Res & Dev | MIXTURES OF POLYPEPTIDES, compositions containing them and methods for their preparation, and uses thereof |
| WO2006050122A1 (en) | 2004-10-29 | 2006-05-11 | Sandoz Ag | Processes for preparing glatiramer |
| US20060172942A1 (en) | 2005-02-02 | 2006-08-03 | Teva Pharmaceutical Industries, Ltd. | Process for producing polypeptide mixtures using hydrogenolysis |
| US20100167983A1 (en) | 2007-10-22 | 2010-07-01 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
| HRP20130622T1 (en) | 2005-02-17 | 2013-08-31 | Teva Pharmaceutical Industries Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
| EP1891233A4 (en) | 2005-04-25 | 2010-03-24 | Yeda Res & Dev | MARKERS ASSOCIATED WITH THERAPY EFFECTIVENESS OF GLATIRAMERATE ACETATE |
| WO2007030573A2 (en) | 2005-09-09 | 2007-03-15 | Yeda Research And Development Co. Ltd. | Polypeptides useful for molecular weight determinations |
| US20070161566A1 (en) | 2006-01-11 | 2007-07-12 | Teva Pharmaceutical Industries, Ltd. | Method of treating multiple sclerosis |
| WO2007146331A1 (en) | 2006-06-12 | 2007-12-21 | Teva Pharmaceutical Industries, Ltd. | Tannate salt form of polypeptide mixtures, their preparation and use |
| TWI498137B (zh) | 2006-06-30 | 2015-09-01 | Abbvie Biotechnology Ltd | 自動注射裝置 |
| ES2338488T3 (es) | 2006-07-05 | 2010-05-07 | Momenta Pharmaceuticals, Inc. | Proceso mejorado para la preparacion de copolimero-1. |
| JP2010540634A (ja) * | 2007-10-01 | 2010-12-24 | ザ・ジョンズ・ホプキンス・ユニバーシティー | シクロホスファミドを用いて自己免疫神経疾患を処置する方法 |
| US8920373B2 (en) | 2009-07-15 | 2014-12-30 | Teva Pharmaceutical Industries, Ltd. | Reduced volume formulation of glatiramer acetate and methods of administration |
| PL2275086T3 (pl) | 2009-07-15 | 2012-09-28 | Teva Pharma | Formulacja octanu glatirameru o zredukowanej objętości oraz sposoby podawania |
| SG10201405806SA (en) | 2009-08-20 | 2014-11-27 | Yeda Res & Dev | Low Frequency Glatiramer Acetate Therapy |
| US8759302B2 (en) | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| ES2602977T3 (es) | 2010-10-11 | 2017-02-23 | Teva Pharmaceutical Industries Ltd. | Biomarcadores de citocinas como biomarcadores predictivos de la respuesta clínica para acetato de glatirámero |
| AU2012323345A1 (en) | 2011-10-10 | 2014-05-22 | Teva Pharmaceutical Industries Ltd. | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
| MX2015004563A (es) | 2012-10-10 | 2015-07-14 | Teva Pharma | Biomarcadores predictivos para respuesta clinica para acetato de glatiramero. |
| EP2941274A4 (en) | 2013-01-04 | 2016-11-16 | Teva Pharma | CHARACTERIZATION OF A MEDICINAL PRODUCT ASSOCIATED WITH GLATIRAMÈRE ACETATE |
| TW201521757A (zh) | 2013-03-12 | 2015-06-16 | Teva Pharma | 先後通過利妥昔單抗（ｒｉｔｕｘｉｍａｂ）誘導治療及格拉默醋酸鹽（ｇｌａｔｉｒａｍｅｒ ａｃｅｔａｔｅ）治療 |
-
2010
- 2010-08-19 SG SG10201405806SA patent/SG10201405806SA/en unknown
- 2010-08-19 KR KR1020177031069A patent/KR20170123354A/ko not_active Ceased
- 2010-08-19 CN CN2010800369660A patent/CN102625657A/zh active Pending
- 2010-08-19 CZ CZ2015-31885U patent/CZ29723U1/cs not_active IP Right Cessation
- 2010-08-19 PL PL13166080T patent/PL2630962T3/pl unknown
- 2010-08-19 LT LTEP13166080.5T patent/LT2630962T/lt unknown
- 2010-08-19 ES ES17157735.6T patent/ES2689711T3/es active Active
- 2010-08-19 AU AU2010284666A patent/AU2010284666B2/en not_active Withdrawn - After Issue
- 2010-08-19 PT PT151710654T patent/PT2949335T/pt unknown
- 2010-08-19 DK DK17157735.6T patent/DK3199172T3/en active
- 2010-08-19 MX MX2012002082A patent/MX2012002082A/es active IP Right Grant
- 2010-08-19 SI SI201030270T patent/SI2405749T1/sl unknown
- 2010-08-19 RS RS20130293A patent/RS52885B/sr unknown
- 2010-08-19 WO PCT/US2010/002283 patent/WO2011022063A1/en not_active Ceased
- 2010-08-19 DK DK13166080.5T patent/DK2630962T3/en active
- 2010-08-19 DK DK15171065.4T patent/DK2949335T3/en active
- 2010-08-19 HU HUE17157735A patent/HUE039335T2/hu unknown
- 2010-08-19 CA CA2760802A patent/CA2760802C/en active Active
- 2010-08-19 AT ATGM50231/2015U patent/AT15421U1/de not_active IP Right Cessation
- 2010-08-19 HU HUE15171065A patent/HUE031282T2/hu unknown
- 2010-08-19 EP EP17157735.6A patent/EP3199172B1/en not_active Revoked
- 2010-08-19 SI SI201031375A patent/SI2949335T1/sl unknown
- 2010-08-19 BR BR112012003730-7A patent/BR112012003730A2/pt not_active Application Discontinuation
- 2010-08-19 CZ CZ2016-33036U patent/CZ30474U1/cs not_active IP Right Cessation
- 2010-08-19 EA EA201270292A patent/EA019998B9/ru not_active IP Right Cessation
- 2010-08-19 EP EP15171065.4A patent/EP2949335B1/en not_active Revoked
- 2010-08-19 DK DK10810282.3T patent/DK2405749T3/da active
- 2010-08-19 ME MEP-2017-17A patent/ME02662B/me unknown
- 2010-08-19 KR KR1020167006001A patent/KR20160038057A/ko not_active Ceased
- 2010-08-19 KR KR1020147012452A patent/KR20140061559A/ko not_active Ceased
- 2010-08-19 PL PL17157735T patent/PL3199172T3/pl unknown
- 2010-08-19 EP EP13166080.5A patent/EP2630962B1/en not_active Revoked
- 2010-08-19 EA EA201400394A patent/EA032283B1/ru unknown
- 2010-08-19 LT LTEP15171065.4T patent/LT2949335T/lt unknown
- 2010-08-19 ES ES10810282T patent/ES2424692T3/es active Active
- 2010-08-19 SI SI201031719T patent/SI2630962T1/sl unknown
- 2010-08-19 DE DE202010018377.4U patent/DE202010018377U1/de not_active Ceased
- 2010-08-19 SG SG2012011425A patent/SG178495A1/en unknown
- 2010-08-19 HR HRP20130677AT patent/HRP20130677T1/hr unknown
- 2010-08-19 ES ES15171065.4T patent/ES2612001T4/es active Active
- 2010-08-19 PL PL10810282T patent/PL2405749T3/pl unknown
- 2010-08-19 KR KR1020127007115A patent/KR20120090044A/ko not_active Ceased
- 2010-08-19 SI SI201031740T patent/SI3199172T1/sl unknown
- 2010-08-19 RS RS20170053A patent/RS55607B1/sr unknown
- 2010-08-19 NZ NZ598661A patent/NZ598661A/xx unknown
- 2010-08-19 JP JP2012525530A patent/JP6038653B2/ja active Active
- 2010-08-19 ES ES13166080.5T patent/ES2688873T3/es active Active
- 2010-08-19 SM SM20170057T patent/SMT201700057T1/it unknown
- 2010-08-19 PT PT108102823T patent/PT2405749E/pt unknown
- 2010-08-19 CN CN201610104429.4A patent/CN105770855A/zh active Pending
- 2010-08-19 LT LTEP17157735.6T patent/LT3199172T/lt unknown
- 2010-08-19 PL PL15171065T patent/PL2949335T3/pl unknown
- 2010-08-19 EA EA201691347A patent/EA032287B1/ru unknown
- 2010-08-19 EP EP18179172.4A patent/EP3409286B1/en not_active Revoked
- 2010-08-19 PT PT17157735T patent/PT3199172T/pt unknown
- 2010-08-19 UA UAA201203259A patent/UA103699C2/ru unknown
- 2010-08-19 US US12/806,684 patent/US8399413B2/en not_active Expired - Fee Related
- 2010-08-19 ME MEP-2013-81A patent/ME01536B/me unknown
- 2010-08-19 EP EP10810282.3A patent/EP2405749B1/en not_active Revoked
- 2010-08-19 PT PT131660805T patent/PT2630962T/pt unknown
- 2010-08-19 CA CA2876966A patent/CA2876966A1/en not_active Abandoned
- 2010-08-19 CN CN201610878988.0A patent/CN107050423A/zh active Pending
- 2010-08-20 TW TW103138861A patent/TWI643614B/zh not_active IP Right Cessation
- 2010-08-20 TW TW106100768A patent/TW201733575A/zh unknown
- 2010-08-20 TW TW099128023A patent/TWI477273B/zh active
- 2010-08-20 AR ARP100103062A patent/AR077896A1/es not_active Application Discontinuation
-
2011
- 2011-11-30 US US13/308,299 patent/US8232250B2/en not_active Expired - Fee Related
-
2012
- 2012-02-14 IL IL218106A patent/IL218106A0/en active IP Right Grant
-
2013
- 2013-02-19 US US13/770,677 patent/US8969302B2/en not_active Expired - Fee Related
- 2013-07-22 CY CY20131100615T patent/CY1114537T1/el unknown
-
2014
- 2014-02-26 HK HK19100376.3A patent/HK1258008A1/en unknown
- 2014-06-30 IL IL233468A patent/IL233468A0/en unknown
-
2015
- 2015-01-12 AR ARP150100073A patent/AR099078A2/es not_active Application Discontinuation
- 2015-02-24 US US14/630,326 patent/US20150164977A1/en not_active Abandoned
- 2015-03-30 US US14/673,257 patent/US9402874B2/en active Active
- 2015-05-13 JP JP2015098415A patent/JP6169644B2/ja active Active
- 2015-05-22 US US14/720,556 patent/US9155776B2/en not_active Expired - Fee Related
- 2015-12-18 SK SK50135-2015U patent/SK501352015U1/sk unknown
-
2016
- 2016-01-06 DK DK201600003U patent/DK201600003Y3/da not_active IP Right Cessation
- 2016-05-06 US US15/148,215 patent/US20160250251A1/en not_active Abandoned
- 2016-12-01 HK HK16113727.5A patent/HK1225310A1/zh unknown
- 2016-12-15 US US15/380,579 patent/US20170095523A1/en not_active Abandoned
-
2017
- 2017-01-13 HR HRP20170056TT patent/HRP20170056T2/hr unknown
- 2017-01-16 CY CY20171100052T patent/CY1118529T1/el unknown
- 2017-01-25 SM SM201700057T patent/SMT201700057B/it unknown
- 2017-02-22 JP JP2017031335A patent/JP2017132773A/ja not_active Withdrawn
- 2017-03-27 US US15/469,758 patent/US20170196803A1/en not_active Abandoned
- 2017-04-26 IL IL251943A patent/IL251943A0/en unknown
- 2017-07-05 US US15/642,201 patent/US20170296464A1/en not_active Abandoned
- 2017-11-13 US US15/811,495 patent/US20180064639A1/en not_active Abandoned
-
2018
- 2018-02-28 US US15/908,441 patent/US20180185274A1/en not_active Abandoned
- 2018-06-27 US US16/020,591 patent/US20180311149A1/en not_active Abandoned
- 2018-08-06 HR HRP20181254TT patent/HRP20181254T1/hr unknown
- 2018-08-06 HR HRP20181253TT patent/HRP20181253T1/hr unknown
- 2018-10-19 US US16/165,541 patent/US20190054013A1/en not_active Abandoned
-
2019
- 2019-02-11 US US16/272,786 patent/US20190175494A1/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050014694A1 (en) * | 2000-06-05 | 2005-01-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| US20070037740A1 (en) * | 2003-03-04 | 2007-02-15 | Irit Pinchasi | Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis |
| US20090048181A1 (en) * | 2004-09-02 | 2009-02-19 | Schipper Hyman M | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis |
| US20090149541A1 (en) * | 2007-11-28 | 2009-06-11 | Yafit Stark | Method of delaying the onset of clinically definite multiple sclerosis |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA103699C2 (ru) | Терапия глатирамера ацетатом с низкой частотой | |
| Chen et al. | The nociceptive and anti-nociceptive effects of bee venom injection and therapy: a double-edged sword | |
| WO2012093258A3 (en) | Irf5- related treatment and screening | |
| NZ703153A (en) | Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof | |
| WO2011069141A3 (en) | Interferon therapies in combination with blockade of stat3 activation | |
| PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
| MX2010005676A (es) | Metodo para retrasar el comienzo de esclerosis multiple clinicamente definida. | |
| NZ603399A (en) | Pegylated c-peptide | |
| EA201400030A1 (ru) | Способ непрерывного подкожного введения инсулина с использованием фермента, разрушающего хиалуронан | |
| HRP20120349T1 (hr) | Formulacija glatiramer acetata smanjenog volumenai postupci davanja | |
| JP2012532859A5 (enExample) | ||
| MX392388B (es) | Metodo cosmetico para el tratamiento o reduccion de paniculopatia edemato-fibroesclerotica (pefe) | |
| BR112014018485A8 (pt) | Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf | |
| NZ700824A (en) | Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients | |
| UA105191C2 (ru) | Лечение пирфенидоном пациентов с атипической функцией печени | |
| JP2015532293A5 (ja) | 糖尿病患者における心不全の治療用組成物 | |
| RU2015116264A (ru) | Композиции и способы лечения сердечной недостаточности у пациентов с диабетом | |
| JP2013520447A5 (enExample) | ||
| NZ604009A (en) | A combination composition comprising ibuprofen and paracetamol | |
| EA201990217A3 (ru) | Терапия глатирамером ацетатом с низкой кратностью | |
| AR122567A2 (es) | Terapia de baja frecuencia con acetato de glatiramer | |
| MD520Y (en) | Method for postoperative treatment of patients with nephrolithiasis | |
| MX2014001271A (es) | Tratamiento de diabetes de tipo 2 con fty720. | |
| Chakraborty et al. | Injection site lipoatrophy: a rare complication of recombinant human insulin | |
| UA109672C2 (uk) | Застосування кислої лізосомної ліпази для лікування дефіциту кислої лізосомної ліпази у хворих |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TH4A | Publication of the corrected specification to eurasian patent | ||
| MF4A | Revocation of a eurasian patent as invalid entirely |
Designated state(s): RU |
|
| RL4A | Court decisions rendered in respect of a eurasian patent |
Designated state(s): RU Free format text: IT WAS DECIDED TO CANCEL THE DECISION OF THE FEDERAL SERVICE FOR INTELLECTUAL PROPERTY DATED 2019.01.30 ON RECOGNIZING THE EURASIAN PATENT NO. 019998 AS INVALID ENTIRELY ON THE TERRITORY OF THE RUSSIAN FEDERATION. |
|
| QB4A | Registration of a licence in a contracting state |